In chronic myeloid leukemia (CML), a mutant fusion gene, Bcr-abl, codes for a constitutively active tyrosine kinase, BCR-ABL, whose inhibition by the drug imatinib mesylate (IM) dramatically reduces the cancer burden (34). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.